Tuberous Sclerosis Complex Market on Track for Major Expansion by 2034, According to DelveInsight | Nobelpharma, Marinus Pharmaceuticals, Noema Pharma, Novartis, Jazz Pharmaceuticals, GRIN Therapeutics, Inc, Longboard Pharmaceuticals

DelveInsight's "Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Tuberous Sclerosis Complex, historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Tuberous Sclerosis Complex market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tuberous Sclerosis Complex Market Forecast
https://www.delveinsight.com/sample-request/tuberous-sclerosis-complex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Tuberous Sclerosis Complex Market Report:
• The Tuberous Sclerosis Complex market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In August 2024, Jazz Pharmaceuticals' attempts to secure approval for its canabidiol therapy in Japan have encountered a setback after a Phase III trial did not achieve its primary endpoint. This trial assessed the canabidiol oral solution as an additional treatment for seizures related to Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in pediatric patients. The study did not reach its primary endpoint, which involved a predetermined percentage change in seizure frequency associated with these conditions during the 16-week treatment period compared to baseline.
• In March 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology firm focused on oncology, has announced that it has signed an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company that specializes in central nervous system (CNS) disorders. This agreement is aimed at developing, manufacturing, and commercializing paxalisib as a potential treatment for intractable epilepsy associated with focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC). The root causes of FCD T2 and TSC are linked to somatic mutations in the PI3K/Akt/mTOR pathway or alterations in the TSC1 or TSC2 genes, which result in overactivation of the mTOR pathway. Paxalisib is an oral dual inhibitor that targets both PI3K and mTOR within this pathway and is notable for its ability to penetrate the brain.
• According to Togi et al. (2022), Tuberous Sclerosis Complex (TSC) occurs in an estimated frequency of approximately one in 6000 to 10,000 individuals in the Japanese population. Among these cases, around two-thirds are sporadic, occurring randomly, while the remaining cases are found within families where there is a genetic predisposition to the condition.
• According to the National Organization for Rare Disorders (NORD), Tuberous Sclerosis Complex (TSC) is a rare genetic disorder affecting 1 in 6,000 newborns in the United States. It is estimated that between 40,000 to 80,000 people in the United States have TSC. In Europe, the prevalence is estimated to range from approximately 1 in 25,000 to 1 in 11,300 individuals.
• According to Orphanet, a database specializing in rare diseases and orphan drugs, the prevalence of Tuberous Sclerosis Complex (TSC) in the UK is estimated to be around 1 in 20,000 to 25,000 individuals.
• Key Tuberous Sclerosis Complex Companies: Nobelpharma, Marinus Pharmaceuticals, Noema Pharma, Novartis, Jazz Pharmaceuticals, GRIN Therapeutics, Inc, Longboard Pharmaceuticals, Aadi Bioscience, Inc., and others
• Key Tuberous Sclerosis Complex Therapies: NPC-12Y gel, Ganaxolone, Basimglurant (NOE-101), everolimus, Canabidiol Oral Solution, Radiprodil, LP352, bexicaserin, nab-sirolimus, and others
• The Tuberous Sclerosis Complex market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tuberous Sclerosis Complex pipeline products will significantly revolutionize the Tuberous Sclerosis Complex market dynamics.

Tuberous Sclerosis Complex Overview
Tuberous Sclerosis Complex (TSC) is a rare genetic disorder characterized by the growth of benign tumors in multiple organs of the body. These tumors can develop in various organs, including the brain, skin, kidneys, heart, eyes, lungs, and other organs.

Get a Free sample for the Tuberous Sclerosis Complex Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Tuberous Sclerosis Complex Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Tuberous Sclerosis Complex Epidemiology Segmentation:
The Tuberous Sclerosis Complex market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Tuberous Sclerosis Complex
• Prevalent Cases of Tuberous Sclerosis Complex by severity
• Gender-specific Prevalence of Tuberous Sclerosis Complex
• Diagnosed Cases of Episodic and Chronic Tuberous Sclerosis Complex

Download the report to understand which factors are driving Tuberous Sclerosis Complex epidemiology trends @ Tuberous Sclerosis Complex Epidemiology Forecast
https://www.delveinsight.com/sample-request/tuberous-sclerosis-complex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Tuberous Sclerosis Complex Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tuberous Sclerosis Complex market or expected to get launched during the study period. The analysis covers Tuberous Sclerosis Complex market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Tuberous Sclerosis Complex Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Tuberous Sclerosis Complex Therapies and Key Companies
• NPC-12Y gel: Nobelpharma
• Ganaxolone: Marinus Pharmaceuticals
• Basimglurant (NOE-101): Noema Pharma
• everolimus: Novartis
• Canabidiol Oral Solution: Jazz Pharmaceuticals
• Radiprodil: GRIN Therapeutics, Inc.
• LP352, bexicaserin: Longboard Pharmaceuticals
• nab-sirolimus: Aadi Bioscience, Inc.

Discover more about therapies set to grab major Tuberous Sclerosis Complex market share @ Tuberous Sclerosis Complex Treatment Landscape
https://www.delveinsight.com/sample-request/tuberous-sclerosis-complex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Tuberous Sclerosis Complex Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Tuberous Sclerosis Complex Companies: Nobelpharma, Marinus Pharmaceuticals, Noema Pharma, Novartis, Jazz Pharmaceuticals, GRIN Therapeutics, Inc, Longboard Pharmaceuticals, Aadi Bioscience, Inc., and others
• Key Tuberous Sclerosis Complex Therapies: NPC-12Y gel, Ganaxolone, Basimglurant (NOE-101), everolimus, Canabidiol Oral Solution, Radiprodil, LP352, bexicaserin, nab-sirolimus, and others
• Tuberous Sclerosis Complex Therapeutic Assessment: Tuberous Sclerosis Complex current marketed and Tuberous Sclerosis Complex emerging therapies
• Tuberous Sclerosis Complex Market Dynamics: Tuberous Sclerosis Complex market drivers and Tuberous Sclerosis Complex market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Tuberous Sclerosis Complex Unmet Needs, KOL's views, Analyst's views, Tuberous Sclerosis Complex Market Access and Reimbursement

To know more about Tuberous Sclerosis Complex companies working in the treatment market, visit @ Tuberous Sclerosis Complex Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/tuberous-sclerosis-complex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Tuberous Sclerosis Complex Market Report Introduction
2. Executive Summary for Tuberous Sclerosis Complex
3. SWOT analysis of Tuberous Sclerosis Complex
4. Tuberous Sclerosis Complex Patient Share (%) Overview at a Glance
5. Tuberous Sclerosis Complex Market Overview at a Glance
6. Tuberous Sclerosis Complex Disease Background and Overview
7. Tuberous Sclerosis Complex Epidemiology and Patient Population
8. Country-Specific Patient Population of Tuberous Sclerosis Complex
9. Tuberous Sclerosis Complex Current Treatment and Medical Practices
10. Tuberous Sclerosis Complex Unmet Needs
11. Tuberous Sclerosis Complex Emerging Therapies
12. Tuberous Sclerosis Complex Market Outlook
13. Country-Wise Tuberous Sclerosis Complex Market Analysis (2020-2034)
14. Tuberous Sclerosis Complex Market Access and Reimbursement of Therapies
15. Tuberous Sclerosis Complex Market Drivers
16. Tuberous Sclerosis Complex Market Barriers
17. Tuberous Sclerosis Complex Appendix
18. Tuberous Sclerosis Complex Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Tuberous Sclerosis Complex Pipeline https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Tuberous Sclerosis Complex Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Tuberous Sclerosis Complex market. A detailed picture of the Tuberous Sclerosis Complex pipeline landscape is provided, which includes the disease overview and Tuberous Sclerosis Complex treatment guidelines.

Tuberous Sclerosis Complex Epidemiology https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Tuberous Sclerosis Complex Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Tuberous Sclerosis Complex epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing - Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance Drug Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market
DelveInsight's "Tongue Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tongue Cancer, historical and forecasted epidemiology as well as the Tongue Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.